



# HOT TOPICS IN HIV

Vaccines, immune recovery  
and eradication

**14<sup>th</sup> October 2021**  
**Casa Convalescència, Barcelona**

More information and registration at:  
[fls-science.com/hot-topics-2021](https://fls-science.com/hot-topics-2021)

## Scientific program

MORNING SESSION		
<i>Registration and coffee</i>		
10.45h	Welcome	<b>Bonaventura Clotet</b> , IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Hospital, UVic-UCC, Spain & <b>Javier Martinez-Picado</b> , IrsiCaixa AIDS Research Institute, ICREA, UVic-UCC, Spain
<b>BLOCK 1: BREAKTHROUGHS IN HIV-1 PATHOGENESIS AND TREATMENT</b>		<b>Chair: Javier Martinez-Picado</b> , IrsiCaixa AIDS Research Institute, ICREA, UVic-UCC, Spain
11.00h-12.00h	Tackling HIV persistence: from mechanism to novel therapeutic strategies	<b>Bonnie Howell</b> , Merck & Co, Boston, MA, USA
	Immunometabolism and HIV-1 pathogenesis	<b>Asier Sáez-Ciri3n</b> , Institut Pasteur, France
<b>BLOCK 2: UNDERSTANDING AND TARGETING HIV-1 RESERVOIRS</b>		<b>Chair: Sara Mor3n-L3pez</b> , IrsiCaixa AIDS Research Institute, Spain
12.00h-13.30h	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART	<b>Roger D. Kouyos</b> , University Hospital Zurich, Switzerland
	Pharmacological approaches to target and eliminate the reservoir	<b>Tokameh Mahmoudi</b> , Erasmus MC, Netherlands
	Role of Tyrosine kinase inhibitors in the control of the viral reservoir	<b>Mayte Coiras</b> , Instituto de Salud Carlos III, Madrid, Spain
13.30h-14.30h	<i>Lunch break</i>	

AFTERNOON SESSION		
<b>BLOCK 3: UPDATE ON COVID-19</b>		<b>Chair: Bonaventura Clotet,</b> IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Hospital, UVic-UCC, Spain
<b>14.30h-15.00h</b>	Prevention and pharmacological treatment of COVID-19	<b>Jose Maria Miró,</b> Hospital Clínic de Barcelona, Spain
<b>BLOCK 4: IMMUNOTHERAPIES TO PUT HIV-1 IN CHECK</b>		<b>Chair: Marta Massanella,</b> IrsiCaixa AIDS Research Institute, Spain
<b>15.00h-16.30h</b>	The Identity of Human Tissue-Emigrant CD8+ T Cells (Cell)	<b>Marcus Buggert,</b> Karolinska Institutet, Sweden
	Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission	<b>Ole Sogaard,</b> Aarhus University Hospital, Denmark
	AELIX-002 Study: HTI Therapeutic Vaccine in Early-treated HIV	<b>Beatriz Mothe,</b> IrsiCaixa Research Institute, Spain
<b>16.30h-17.00h</b>	<i>Why bet on research in the cure of HIV?</i>	<b>Mario Stevenson,</b> University of Miami, USA
<b>17.00h</b>	Closing and farewell drink	

Thanks to the support of

